Gain-of-function mutations in the V2 vasopressin receptor

Hormone Research

Volumn 67, Issue SUPPL. 1, 2007, Pages 121-125

  Rosenthal, Stephen M ^a,b   Gitelman, Stephen E ^a   Vargas, Gabriel A ^b   Feldman, Brian J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antidiuresis; Hyponatremia; Inappropriate secretion of antidiuretic hormone; Nephrogenic syndrome of inappropriate antidiuresis; Vasopressin receptor

Indexed keywords

ARGIPRESSIN; CALCIUM SENSING RECEPTOR; CHORIONIC GONADOTROPIN; DESMOPRESSIN; G PROTEIN COUPLED RECEPTOR; THYROTROPIN; UREA; VASOPRESSIN V2 RECEPTOR; VON WILLEBRAND FACTOR;

ANTIDIURESIS; CONFERENCE PAPER; DIABETES INSIPIDUS; ENDOCRINE DISEASE; FLUID BALANCE; GENE MUTATION; GENE SEQUENCE; HUMAN; HYPERPARATHYROIDISM; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INCIDENCE; MISSENSE MUTATION; NEPHROGENIC SYNDROME OF INAPPROPRIATE ANTIDIURESIS; NONHUMAN; PRIORITY JOURNAL; THYROTOXICOSIS;

EID: 33847027881     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097567     Document Type: Conference Paper

References (24)

1. Baylis PH: The syndrome of inappropriate antidiuretic hormone secretion. Int J Biochem Cell Biol 2003;35:1495-1499.
2. Verbalis JG: Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab 2003;17:471-503.
3. Schrier RW, Cadnapaphornchai MA: Renal aquaporin water channels: from molecules to human disease. Prog Biophys Mol Biol 2003;81:117-131.
4. Feldman BJ, Rosenthal SM, Vargas GA, Fenwick RG, Huang EA, Matsuda-Abdini M, Lustig RH, Mathias RS, Portale AA, Miller WL, Gitelman SE: Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 2005;352:1884-1890.
5. Huang EA, Feldman BJ, Schwartz ID, Geller DH, Rosenthal SM, Gitelman SE: Oral urea for the treatment of chronic syndrome of inappropriate antidiuresis in children. J Pediatr 2006;148:128-131.
6. Morello JP, Bichet DG: Nephrogenic diabetes insipidus. Annu Rev Physiol 2001;63:607-630.
7. Knoers NVAM: Hyperactive vasopressin receptors and disturbed water homeostasis. N Engl J Med 2005;352:1847-1850.
8. Rosenthal W, Antaramian A, Gilbert S, Birnbaumer M: Nephrogenic diabetes insipidus. A V2 vasopressin receptor unable to stimulate adenylyl cyclase. J Biol Chem 1993;268:13030-13033.
9. Themmen APN, Huhtaniemi IT: Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function. Endocr Rev 2000;21:551-583.
10. Shenker A, Laue L, Kosugi S, Merendino JJ Jr, Minegishi T, Cutler GB Jr: A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 1993;365:652-654.
11. Spiegel AM, Weinstein LS: Inherited diseases involving G proteins and G-protein coupled receptors. Annu Rev Med 2004;55: 27-39.
12. Tapanainen JS, Aittomaki K, Min J, Vaskivuo T, Huhtaniemi IT: Men homozygous for an inactivating mutation of the follicle stimulating hormone (FSH) receptor gene present variable suppression of spermatogenesis and fertility. Nat Genet 1997;15:205-206.
13. Smits G, Olatunbosun O, Delbaere A, Pierson R, Vassart G, Costagliola S: Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. N Engl J Med 2003;349:760-766.
14. Simoni M, Gromoll J, Nieschlag E: The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology and pathophysiology. Endocr Rev 1997;18:739-773.
15. Rodien P, Jordan N, Lefevre A, Royer J, Vasseur C, Savagner F, Bourdelot A, Rohmer V: Abnormal stimulation of the thyrotrophin receptor during gestation. Hum Reprod Update 2004;10:95-105.
16. 2+-sensing receptor: implications for its structure and function. Trends Endocrinol Metab 2003;14:282-288.
17. Hirsch AT, Dzau VJ, Majzoub JA, Creager MA: Vasopressin-mediated forearm vasodilation in normal humans: evidence for a vascular vasopressin V2 receptor. J Clin Invest 1989;84:418-426.
18. Kaufmann JE, Iezzi M, Vischer UM: Desmopressin (DDAVP) induces NO production in human endothelial cells via V2 receptors and cAMP-mediated signaling. J Thromb Haemost 2003;1:821-828.
19. Mannucci PM, Ruggeri AM, Pareti FI, Capitanio A: 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet 1977;1:869-872.
20. Bichet DG, Razi M, Lonergan M, Arthus MF, Papukna V, Kortas C, Barjon JN: Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus. N Engl J Med 1988;318:881-887.
21. Zerbe R, Stropes L, Robertson G: Vasopressin function in the syndrome of inappropriate antidiuresis. Annu Rev Med 1980;31:315-327.
22. Greenberg A, Verbalis JG: Vasopressin receptor antagonists. Kidney Int 2006;69:2124-2130.
23. Morin D, Cotte N, Balestre MN, Mouillac B, Manning M, Breton C, Barberis C: The D136A mutation of the V2 vasopressin receptor induces a constitutive activity which permits discrimination between antagonists with partial agonist and inverse agonist activities. FEBS Lett 1998;441:470-475.
24. Decaux G, Prospert F, Penninckx R, Namias B, Soupart A: Five-year treatment of the chronic syndrome of inappropriate secretion of ADH with oral urea. Nephron 1993;63:468-470.